© 2002 by Oxford University Press
Journal of the National Cancer Institute, Vol. 94, No. 22, 1659,
November 20, 2002
© 2002 Oxford University Press
Press Release
Imatinib Shows Early Promise Against Ewing’s Sarcoma
jncimedia{at}oupjournals.org
Imatinib mesylate, also known as Gleevec, is showing early signs of promise in preclinical trials against Ewing’s sarcoma, a bone tumor in children and adolescents. In a study in the November 20 issue of the Journal of the National Cancer Institute, treatment with imatinib induced cell death in all Ewing’s sarcoma cell lines tested and substantial tumor shrinkage in mice.
Imatinib is a tyrosine kinase inhibitor that has produced high response rates in patients with chronic myelogenous leukemia and gastrointestinal stromal tumors. Both cancers are associated with the overactivation of a specific tyrosine kinase. In Ewing’s sarcoma, overactivation of the c-kit receptor tyrosine kinase contributes to tumor growth and tumor cell proliferation.
Melinda S. Merchant, M.D., Ph.D., of the National Cancer Institute, and her colleagues examined whether imatinib inhibited tumor growth and cell proliferation of Ewing’s sarcoma by testing the drug in 10 mice bearing human Ewing’s sarcoma tumors and in 10 Ewing’s sarcoma cell lines.
Treatment with imatinib caused cell death in all cell lines tested, including those resistant to chemotherapy. "This observation is especially important because chemoresistance is a major contributor to the rate of treatment failure in recurrent Ewing’s sarcoma," the authors say. Treatment with imatinib also blocked activation of the c-kit receptor tyrosine kinase and resulted in substantial tumor shrinkage in mice bearing human Ewing’s sarcoma tumors.
The authors note that higher concentrations of imatinib were needed to kill Ewing’s sarcoma cells than other tumor cells but that "even if the toxicity of higher doses of imatinib proves intolerable for clinical translation of these results, the identification of the target or targets of imatinib that lead to cytotoxicity in Ewing’s sarcoma may allow the design of related compounds with increased specificity to induce death of Ewing’s sarcoma cells."
In an accompanying editorial, Brian Druker, M.D., of the Oregon Health and Science University Cancer Institute in Portland, points out that the concentrations of imatinib required to inhibit cell proliferation and to block c-kit activation suggest that c-kit is not the primary target of imatinib and that such high concentrations may not be achievable in the clinical setting.
The promise, he concludes, is that identification of another imatinib-sensitive kinase in Ewing’s sarcoma cells could lead to improved therapy for this disease.
###
Contact: NCI Office of Communications, (301) 496-6641; fax: (301) 496-0846, ncipressofficers{at}mail.nih.gov.
Editorial: Martin Munguia, Oregon Health and Science University, (503) 494-8231; fax: (503) 494-8246, munguiam{at}ohsu.edu
Merchant M, Woo C, Mackall C, Thiele C. Potential use of imatinib in Ewing’s Sarcoma: Evidence for in vitro and in vivo activity. J Natl Cancer Inst 2002;94:1673–9.
Editorial: Druker B. Taking aim at Ewing’s Sarcoma: Is KIT a target and will imatinib work? J Natl Cancer Inst 2002;94:1660–1.
Note: The Journal of the National Cancer Institute is published by Oxford University Press and is not affiliated with the National Cancer Institute. Attribution to the Journal of the National Cancer Institute is requested in all news coverage.
CiteULike 
Connotea 
Del.icio.us What's this?
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||